Cargando…

Patients’ perspectives towards biologic dose reduction in psoriasis: a qualitative study

Dose reduction of biologics for psoriasis could contribute to more efficient use of these expensive medicines. Evidence on opinions of patients with psoriasis regarding dose reduction is sparse. The objective of this study was therefore to explore patients’ perspectives towards dose reduction of bio...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Schoot, L. S., Verhoef, L. M., van Ee, I., van Oort, F. P. A. H., Pieterse, A. H., Seyger, M. M. B., de Jong, E. M. G. J., van den Reek, J. M. P. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338615/ https://www.ncbi.nlm.nih.gov/pubmed/36813868 http://dx.doi.org/10.1007/s00403-023-02566-w

Ejemplares similares

Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice
por: van der Schoot, L.S., et al.
Publicado: (2023)

Attitudes and behaviour regarding dose reduction of biologics for psoriasis: a survey among dermatologists worldwide
por: van Muijen, M. E., et al.
Publicado: (2021)

Data‐driven prediction of biologic treatment responses in psoriasis: steps towards precision medicine
por: van der Schoot, L. S., et al.
Publicado: (2021)

Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab
por: van der Schoot, Lara S., et al.
Publicado: (2022)

Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review
por: Michielsens, C. A. J., et al.
Publicado: (2021)

Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice
por: ATALAY, Selma, et al.
Publicado: (2021)

The Effect of Lifestyle Changes on Disease Severity and Quality of Life in Patients with Plaque Psoriasis: A Narrative Review
por: van Acht, Maartje R, et al.
Publicado: (2022)

Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study
por: van der Schoot, Lara S., et al.
Publicado: (2021)

Predicting treatment success with biologics in psoriasis
por: van den Reek, J.M.P.A.
Publicado: (2019)

Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial
por: Atalay, Selma, et al.
Publicado: (2017)

Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab
por: van Muijen, Marloes E., et al.
Publicado: (2021)

Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities
por: Bronckers, I. M. G. J., et al.
Publicado: (2015)

Discovery of Psoriatic Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER) Study: A Prospective Observational Cohort
por: VAN HAL, Tamara W., et al.
Publicado: (2022)

Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study
por: ATALAY, Selma, et al.
Publicado: (2020)

Clinical, laboratory, and genetic markers for the development or presence of psoriatic arthritis in psoriasis patients: a systematic review
por: Mulder, Michelle L. M., et al.
Publicado: (2021)

Highlights of the updated Dutch evidence‐ and consensus‐based guideline on psoriasis 2017
por: van der Kraaij, G.E., et al.
Publicado: (2019)

Development of a New Referral Tool to Identify Psoriasis Patients with Concomitant Psoriatic Arthritis: Results of the Prospective DAPPER Cohort
por: VAN HAL, Tamara W., et al.
Publicado: (2023)

The Skin May Clear But the Arthritis Won’t Disappear: Focusing on Concomitant and New-Onset Psoriatic Arthritis in a Daily Practice Cohort of Psoriasis Patients on Biologic Therapy
por: van Muijen, Marloes E, et al.
Publicado: (2020)

Image‐based automated Psoriasis Area Severity Index scoring by Convolutional Neural Networks
por: Schaap, M.J., et al.
Publicado: (2021)

Blood-Based Immune Profiling Combined with Machine Learning Discriminates Psoriatic Arthritis from Psoriasis Patients
por: Mulder, Michelle L. M., et al.
Publicado: (2021)

Challenges in Noninvasive Skin Biomarker Measurements in Daily Practice: A Longitudinal Study on Skin Surface Protein Detection by the Transdermal Analysis Patch in Pediatric Psoriasis
por: Schaap, Mirjam J., et al.
Publicado: (2022)

Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis
por: VAN MUIJEN, Marloes E., et al.
Publicado: (2022)

Response to: Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?
por: Ismail, R.K., et al.
Publicado: (2022)

Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial
por: Michielsens, Celia A. J., et al.
Publicado: (2020)

Response to IL‐17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein‐coding and untranslated regions of the IL‐17A gene: results from a multicentre study of four European psoriasis cohorts
por: van Vugt, L.J., et al.
Publicado: (2019)

Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER): Protocol for a Longitudinal Observational Study
por: van Hal, Tamara W, et al.
Publicado: (2021)

On-line reductive cyclic voltammetric analysis of the anticancer agents mitomycin C, some of its degradation products and profiromycin
por: Ploegmakers, H. H. J. L., et al.
Publicado: (1987)

Perfusion measured by laser speckle contrast imaging as a predictor for expansion of psoriasis lesions
por: Schaap, Mirjam J., et al.
Publicado: (2021)

Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate‐to‐severe psoriasis: a post hoc analysis from IXORA‐PEDS
por: Seyger, M.M.B., et al.
Publicado: (2021)

Real-world Methotrexate Use in a Prospective Cohort of Paediatric Patients with Plaque Psoriasis: Effectiveness, Adverse Events and Folic Acid Regimen
por: BRUINS, Finola M., et al.
Publicado: (2022)

Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort
por: VAN MUIJEN, Marloes. E., et al.
Publicado: (2022)

Online decision aid for patients with psoriasis
por: van der Kraaij, G.E., et al.
Publicado: (2021)

Safety of ustekinumab in adolescent patients with moderate‐to‐severe plaque psoriasis: real‐world evidence from an ongoing European study (NCT03218488)
por: Mahé, E., et al.
Publicado: (2022)

Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study
por: Michielsens, Celia A J, et al.
Publicado: (2021)

Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review
por: Tweehuysen, Lieke, et al.
Publicado: (2017)

Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer
por: Ismail, R.K., et al.
Publicado: (2021)

Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial
por: Busard, Celine, et al.
Publicado: (2017)

Erratum to: Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial
por: Busard, Celine, et al.
Publicado: (2017)

Safety and efficacy of fixed‐dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open‐label trial
por: Seyger, M., et al.
Publicado: (2020)

Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients—A BioCAPTURE Registry Study
por: ter Haar, E. L. M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_podv9fv1sdu6gtbrkp4bceba2b